Irafamdastat clinical trials
Also written BMS-986368 and CC-97489.
How each study uses irafamdastat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the irafamdastat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2024 (3); 1 more planned to start later
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test irafamdastat.
- Dec 2026A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect on the Pharmacokinetics of Irafamdastat in Healthy Adult ParticipantsPhase 1 · Celgene
- Feb 2027A Study to Evaluate the Blood Levels, Safety, and Tolerability of BMS-986368 in Healthy Chinese ParticipantsPhase 1 · Celgene
- May 2027A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis SpasticityPhase 2 · Celgene
- Nov 2027Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseasePhase 2 · Celgene
Studies
Open first, then newest update. How each study uses irafamdastat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect on the Pharmacokinetics of Irafamdastat in Healthy Adult ParticipantsRecruitingPhase 1CelgeneNCT07837115Written as Irafamdastat
- A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis SpasticityRecruitingPhase 2CelgeneNCT06782490Written as BMS-986368
- Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseaseRecruitingPhase 2CelgeneNCT06808984Written as BMS-986368
- A Study to Evaluate the Blood Levels, Safety, and Tolerability of BMS-986368 in Healthy Chinese ParticipantsNot yet recruitingPhase 1CelgeneNCT07700329Written as BMS-986368
- A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese EthnicityCompletedPhase 1CelgeneNCT06411730Written as BMS-986368
- A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy ParticipantsCompletedPhase 1CelgeneNCT06170723Written as BMS-986368
- A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male ParticipantsCompletedPhase 1CelgeneNCT06227975Written as [14C]-BMS-986368
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult ParticipantsTerminatedPhase 1CelgeneNCT05099822Written as CC-97489
Given beside what is tested · 1 — irafamdastat is usual care or a partner of the new treatment
Codes
What other systems call irafamdastat · ClinicalTrials.gg INT018420
- UNII (FDA) X3Q33L6UL2IRAFAMDASTATOne source FDA
- NCI Thesaurus C215252IrafamdastatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | X3Q33L6UL2 | IRAFAMDASTAT | One source FDA |
| NCI Thesaurus | C215252 | Irafamdastat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.